Dax Eckard, OD
Optometrist · Tupelo, MSNPI 1932102779
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.8% of the total across 213 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 21.0% — the pattern of someone who eats at a lot of different presentations. Among optometrist clinicians in MS with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 213 payments — averaging $22.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mallinckrodt Hospital Products Inc.$1K
- AbbVie$693
- Alcon$401
- Johnson & Johnson Vision Care, Inc.$360
- Bausch & Lomb Americas Inc.$251
- Rxsight Inc$248
- plus $2K from 21 others
What the payments were for
- Speaking & faculty fees$261%
- Food & beverage$4,59695%
- Entertainment$2295%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mallinckrodt Hospital Products Inc. | 50 | $1,018 |
| AbbVie(2 entities) | 36 | $693 |
| Alcon | 20 | $401 |
| Johnson & Johnson Vision Care, Inc. | 15 | $360 |
| Bausch & Lomb Americas Inc. | 8 | $251 |
| Rxsight Inc | 12 | $248 |
| Oyster Point Pharma, Inc. | 8 | $239 |
| Optos, Inc. | 2 | $229 |
| Harrow Eye, LLC | 4 | $179 |
| Novartis | 12 | $170 |
| Glaukos Corporation | 3 | $151 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 5 | $144 |
| Ocular Therapeutix, Inc. | 5 | $101 |
| Eyevance Pharmaceuticals LLC | 2 | $86 |
| Dompe US, Inc. | 2 | $85 |
| Sun Pharmaceutical Industries Inc. | 5 | $80 |
| Aerie Pharmaceuticals, Inc. | 5 | $78 |
| ANI Pharmaceuticals, Inc. | 3 | $65 |
| Biotissue Holdings Inc. | 4 | $53 |
| Tarsus Pharmaceuticals, Inc. | 2 | $45 |
| Coopervision Inc. | 2 | $40 |
| Rayner Intraocular Lenses Limited | 1 | $29 |
| Sight Sciences, Inc. | 2 | $28 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $28 |
| Shire North American Group Inc | 1 | $20 |
| Iridex Corporation | 1 | $16 |
| NEW World Medical,inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,850 in reported general payments places this provider in the 90th percentile of 372 optometrist providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 196 | $76,739 |
| RestasisCyclosporine | 68 | $69,233 |
| CombiganBrimonidine Tartrate/Timolol | 117 | $28,723 |
| XiidraLifitegrast | 17 | $15,695 |
| TyrvayaVarenicline Tartrate | 12 | $8,501 |
| RhopressaNetarsudil Mesylate | 14 | $6,057 |
| Alphagan PBrimonidine Tartrate | 16 | $5,357 |
| Prednisolone Acetate | 175 | $5,170 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 24 | $4,933 |
| Latanoprost | 398 | $3,651 |
| Cyclosporine | 16 | $3,452 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 23 | $3,290 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 145 | $1,827 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 47 | $1,797 |
| Travoprost | 26 | $1,649 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan, Alphagan P | $693 | $180,052397 claims |
| Bausch & Lomb Americas Inc.Xiidra | $251 | $15,69517 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $239 | $8,50112 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa | $78 | $6,05714 claims |
| AlconSimbrinza | $401 | $4,93324 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 372 optometrist providers in Mississippi.
Other optometrist in Tupelo
- Ryan RussellTupelo$5K
- Chelsea McKnightTupelo$4K
- Fred MothershedTupelo$4K
- Kristopher MayColdwater$229K
- Alyssa MabrySenatobia$66K
- Roya AttarJackson$19K
- Deandre CarrByram$9K
- Michael ObrienSouthaven$9K
- George MarchbanksGulfport$9K
- William ArnoldMadison$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.